A real-time dashboard of clinical trials for COVID-19

Thorlund, Kristian; Dron, Louis; Park, Jay; Hsu, Grace; Forrest, Jamie I; Mills, Edward J.

doi:10.1016/s2589-7500(20)30086-8

Cited by 214 publications

(240 citation statements)

References 3 publications

Supporting

Mentioning

234

Contrasting

Unclassified

Order By: Relevance

“…To identify unpublished trials, we searched clinical trial registries (e.g., clinicaltrials.gov, clinicaltrialregister.eu , who.int/ictrp , chictr.org.cn ) of Europe, USA, and China, and websites of pharmaceutical companies, websites of US Food and Drug Administration (FDA) and European Medicines Agency (EMA). We also searched the COVID-19 Study Registry [ 13 ] and the real-time dashboard of randomized trials [ 14 ].…”

Section: Methodsmentioning

confidence: 99%

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

et al. 2020

View full text Add to dashboard Cite

Background Coronavirus disease 2019 (COVID-19) is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. Methods and findings This is the first edition of a living systematic review of randomized clinical trials comparing the effects of all treatment interventions for participants in all age groups with COVID-19. We planned to conduct aggregate data meta-analyses, trial sequential analyses, network meta-analysis, and individual patient data meta-analyses. Our systematic review is based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and Cochrane guidelines, and our 8-step procedure for better validation of clinical significance of meta-analysis results. We performed both fixed-effect and random-effects meta-analyses. Primary outcomes were all-cause mortality and serious adverse events. Secondary outcomes were admission to intensive care, mechanical ventilation, renal replacement therapy, quality of life, and nonserious adverse events. We used Grading of Recommendations Assessment, Development and Evaluation (GRADE) to assess the certainty of evidence. We searched relevant databases and websites for published and unpublished trials until August 7, 2020. Two reviewers independently extracted data and assessed trial methodology. We included 33 randomized clinical trials enrolling a total of 13,312 participants. All trials were at overall high risk of bias. We identified one trial randomizing 6,425 participants to dexamethasone versus standard care. This trial showed evidence of a beneficial effect of dexamethasone on all-cause mortality (rate ratio 0.83; 95% confidence interval [CI] 0.75–0.93; p < 0.001; low certainty) and on mechanical ventilation (risk ratio [RR] 0.77; 95% CI 0.62–0.95; p = 0.021; low certainty). It was possible to perform meta-analysis of 10 comparisons. Meta-analysis showed no evidence of a difference between remdesivir versus placebo on all-cause mortality (RR 0.74; 95% CI 0.40–1.37; p = 0.34, I 2 = 58%; 2 trials; very low certainty) or nonserious adverse events (RR 0.94; 95% CI 0.80–1.11; p = 0.48, I 2 = 29%; 2 trials; low certainty). Meta-analysis showed evidence of a beneficial effect of remdesivir versus placebo on serious adverse events (RR 0.77; 95% CI 0.63–0.94; p = 0.009, I 2 = 0%; 2 trials; very low certainty) mainly driven by respiratory failure in one trial. Meta-analyses and trial sequential analyses showed that we could exclude the possibility that hydroxychloroquine versus standard care reduced the risk of all-cause mortality (RR 1.07; 95% CI 0.97–1.19; p = 0.17; I 2 = 0%; 7 trials; low certainty) and ...

show abstract

Section: Methodsmentioning

confidence: 99%

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

et al. 2020

View full text Add to dashboard Cite

show abstract

“…10,11 Efforts have been made around the globe to enhancethe understanding of the dynamic transmission of COVID-19, appropriate vaccine research strategies effective treatments, as well as the impacts of current responses on population health and well-being. 12 As a result, in the last four months, the number of publications about COVID-19 has been increased dramatically, including articles, reviews, letters to editors, or preprint documents. 13 These contributions have proven the importance of scientific research in pandemic preparedness as well as helping the governments to respond rapidly and effectively to the crisis.…”

Section: Introductionmentioning

confidence: 99%

Studies of Novel Coronavirus Disease 19 (COVID-19) Pandemic: A Global Analysis of Literature

Tran

Nguyen

et al. 2020

Preprint

View full text Add to dashboard Cite

An exponential growth of literature about novel coronavirus disease 19 has been observed in the last few months. This textual analysis of 5,780 publications extracted from the Web of Science, Medline, and Scopus databases was performed to explore the current research focuses and propose further research agenda. The Latent Dirichlet allocation was used for topic modeling. Regression analysis was conducted to examine country variations in the research focuses. Results indicated that publications were mainly contributed by the United States, China, and European countries. Guidelines for emergency care and surgical, viral pathogenesis, and global responses in the COVID-19 pandemic were the most common topics. There was variation in the research approaches to mitigate COVID-19 problems in countries with different income and transmission levels. Findings highlighted the need for global research collaboration among highand low/middle-income countries in the different stages of prevention and control the pandemic.

show abstract

“…To nd an effective treatment for COVID-19 several existing drugs have been assessed and approved for clinical trials through accelerated procedures worldwide 1,2 . These drugs meant to treat non COVID-19 speci c conditions are now given massively to patients affected by COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Risk of pre-term births and major birth defects resulting from paternal intake of COVID-19 medications prior to conception

Rizzi

Wensink

Lindahl-Jacobsen

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective. With the ongoing COVID-19 pandemic, large numbers of people will receive one of the several medications proposed to treat COVID-19, including patients of reproductive age. Given that some medications have shown adverse effects on sperm quality, there might be a transgenerational concern. We aim at examining the association between drugs proposed to treat COVID-19 when taken by the father around conception and any pre-term birth or major birth defects in offspring in a nation-wide cohort study using Danish registry data. Offspring whose father filled at least one prescription of the following medications in the three months preceding conception were considered exposed: chloroquine, hydroxychloroquine, losartan, azithromycin, naproxen, dexamethasone and prednisone. Results. For azithromycin and naproxen, large numbers of offspring were exposed (> 1800 offspring), and we found no association with adverse birth outcomes. For chloroquine, losartan and dexamethasone, exposure was intermediate (~ 900 offspring), and there was no statistically significant association with birth defects. For hydroxychloroquine and prednisone, exposure was limited (< 300 offspring). There is strong evidence that azithromycin and naproxen are safe with respect to pre-term birth and birth defects. With some caution, the other drugs investigated can be considered safe.

show abstract

A real-time dashboard of clinical trials for COVID-19

Cited by 214 publications

References 3 publications

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)

Studies of Novel Coronavirus Disease 19 (COVID-19) Pandemic: A Global Analysis of Literature

Risk of pre-term births and major birth defects resulting from paternal intake of COVID-19 medications prior to conception

Contact Info

Product

Resources

About